摘要
目的 评估脂蛋白 a(LP a)在遗传性凝血酶原缺陷的静脉血栓栓塞 (VTE)病人组中所起的作用。方法 研究对象包括至少发生一次静脉血栓栓塞的病人共 6 85例和 2 6 6例性别和年龄相当 ,并排除存在活化蛋白C(APC)抵抗 ,蛋白C、蛋白S及抗凝血酶缺陷 ,血清LP a升高 ,因子 (F)VG16 91A、二甲基四水叶酸还原酶 (methylenetetrahydrofolatereductase ,MTHFR)C6 77T和凝血酶原 (PT)G2 0 2 10A基因突变等因素的健康人对照组。将其LP a升高及FVG16 91A因子突变作比较。结果 病人组中LP a>0 .30g/L的占 2 0 % ,明显高于对照组 (P <0 .0 0 1,OR3.2 ,95 %CI 1.9～ 5 .3) ;LP a升高 ,同时存在FVG16 91A因子 ,在VTE病人中明显多于对照组 (P <0 .0 0 1,OR9.8,95 %CI2 .4～ 4 0 .7)。结论 LP a >0 .30g/L为VTE的一种常见独立危险因子。此外 ,LP a水平可能与由于受其它凝血因子缺陷 ,如FVG16
Objective To evaluate the role of lipoprotein a(LP a) in a panel of established hereditary thromboembolism(VTE).Methods The study subjects included 685 consecutive patients with at least one episode of VTE and 266 sex and age matched healthy controls were screened with regard to activated protein C resistance,protein C,protein S,and antithrombin deficiency, elevated serum levels of LP a,and the factor V(FV) G1691A,Methylenetetrahydrofolate reductase(MTHFR) C677T,and prothrombin(PT) G20210A gene mutations.Results Elevated LP a levels above 0.30g/L were found in 20% of patients group,there were significantly higher than in the control group( P <0.001,odds ratio [OR]3.2,95%confidence interval [CI]1.9 5.3);the coexistence of FV G1691A and elevated LP a was significantly more prevalent in patients group with VTE than in the control group ( P <0.001, OR 9.8,95%CI 2.4 40.7).Conclusion LP a concentration greater than 0.30g/L is a frequent and independent risk factor for VTE.Furthermore,elevated LP a levels might contribute to the penetrance of thromboembolic disease in subjects being affected by other prothrombotic defects,such as FV G1691A mutation.
出处
《国外医学（临床生物化学与检验学分册）》
CAS
2003年第3期169-171,共3页
Foreign Medical Sciences(section of Clinical Biochemistry and Laboratory Medicine
